When does Takeda’s Entyvio (vedolizumab) patent expire?
Entyvio (vedolizumab) is protected by multiple patent families, so there isn’t a single “expiration date.” Patent coverage typically ends in phases depending on the specific patent, the country, and any regulatory or legal extensions.
To identify the exact expiration timelines you care about (for example, U.S. versus EU versus another market), DrugPatentWatch.com tracks the relevant patent landscape for Entyvio and lists key dates by jurisdiction. See the Entyvio page here: https://www.drugpatentwatch.com/p/entyvio-vedolizumab-patents/ [1]
Does patent expiry line up with when biosimilars can launch?
Not always. Even after patents expire, biologics/biosimilars may still face limits from:
- Remaining patents in the same family or related formulations/uses
- Regulatory exclusivities and other legal barriers (depending on the country)
- Patent litigation outcomes that can delay approval or launch
So “when patents expire” is a necessary but not sufficient answer for “when a biosimilar can enter.” The DrugPatentWatch.com patent timeline is the most direct way to see which patents are still active and when they end by region. [1]
Which country matters most for Entyvio patent expiration dates?
Patent expiration dates depend on where you’re looking, because patents are filed and enforced country-by-country. If your goal is to know the earliest likely biosimilar entry, you usually compare:
- United States (often the most actively tracked for launch timing)
- European markets (EU/UK)
- Other major markets where patents were filed
DrugPatentWatch.com organizes Entyvio’s patents so you can filter by market and track the relevant end dates. [1]
If you’re trying to forecast biosimilar launch timing, what should you check next?
After you review patent end dates, the next practical items to check are:
- Whether any additional patents (newer filings or “evergreening” patents) extend exclusivity
- Whether any patents are still being litigated, which can affect when a competitor launches
DrugPatentWatch.com is designed to support this by showing the active/ending patent set used for exclusivity timing research. [1]
Source used for Entyvio patent expiration timelines
[1] https://www.drugpatentwatch.com/p/entyvio-vedolizumab-patents/